Cell Therapeutics gets FDA clearance to add patients to clinical trial
The Associated Press
Cell Therapeutics stock rose 8 cents or 4.2 percent, to $1.99 Thursday after the drugmaker received notice from the Food and Drug Administration that a partial clinical hold on its potential blood-related cancer treatment tosedostat has been removed and studies on the drug may continue.
The FDA in June ordered Cell Therapeutics to stop enrolling patients in its clinical trial because of the death of a 70-year-old patient from myocarditis, an inflammation of the heart muscle wall.
The FDA requested more information on patients and adverse events in the clinical trial. Cell Therapeutics couldn’t enroll new patients until the agency gave the go-ahead.